Herceptin, tamoxifen, and trastuzumab have been commonly used for clinical treatment of hormone-receptor-positive BC and HER2-positive BC, and have achieved good clinical outcomes to a certain extent. This evidence concerns the gene NR4A1 and breast cancer.